Clinical trials: Nutritional Evaluation
Obesity, Bariatric Surgery
Evaluation of the Dietary Supplement Refill Bypass to Reduce Nutritional Deficiencies of Patients Who Underwent Bariatric Surgery
This is a cohort, observational, prospective, multicenter, longitudinal study. 100 patients will be followed postoperatively for a period of 12 months.
- Trial name
- Refill (NCT02440087)
- Testing
- Refill Bypass
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Refill France
Infantile Malignant Osteopetrosis
A Trial to Evaluate Safety and Efficacy of RP-L401-0120 in Subjects With Infantile Malignant Osteopetrosis
The primary objective of this Phase 1 study is to evaluate the therapeutic safety and feasibility of the investigational product (IP), RP-L401.
- Trial name
- NCT04525352
- Testing
- RP-L401
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rocket Pharmaceuticals Inc.
Peritoneal Dialysis, Hypertriglyceridemia
Effect of Extraneal (Icodextrin)on Triglyceride Levels in PD Patients
This is a Phase IV study evaluating triglyceride levels in peritoneal dialysis patients.
- Trial name
- NCT00397358
- Testing
- Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution
- Where
- 3 sites in United States
- Sponsor
- Vantive Health LLC
Colorectal Neoplasm, Intestinal Neoplasms
Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma
The research product, registered as a nutritional supplement (Ocoxin®, oral solution), manufactured by Laboratorios Catalysis S. L., comes in the form of single-dose vials of 30 ml.
- Conditions
- Colorectal Neoplasm, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasm
- Trial name
- NCT03559543
- Testing
- Ocoxin-Viusid
- Where
- Cuba
- Volunteers
- 40 people
- Sponsor
- Catalysis SL
Atherosclerosis
A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients
The primary objective of this study is to examine the effects of SB-480848 on plasma lipoprotein associated phospholipase A2 (Lp-PLA2) activity in dyslipidemic patients during a 4-week treatment with SB-480848.
- Trial name
- NCT00734032
- Testing
- SB480848 40mg EC Tablet, SB480848 80mg EC Tablet, SB480848 160mg EC Tablet
- Where
- 7 sites in Japan
- Volunteers
- 107 people
- Sponsor
- GlaxoSmithKline
Aging, Mitochondrial Dysfunction
A Single and Multiple Dose Study of AMAZ-02 to Evaluate Safety and Pharmacokinetics in Elderly Subjects
Part A: The study is a double-blind, randomized, single ascending doses, study in 24 healthy elderly male and female volunteers. Each subject will be randomized for two subsequent doses in three cohorts.
- Conditions
- Aging, Mitochondrial Dysfunction, Muscle Function
- Trial name
- NCT02655393
- Testing
- Mitopure
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Amazentis SA
Hypercholesterolemia, Dyslipidemias
A Study to Evaluate the Effectiveness and Safety of Fixed-Dose Combination of Pitavastatin/ Ezetimibe
The objective of this study is to evaluate the effectiveness and safety of Pitavastatin/Ezetimibe FDC in patients with hypercholesterolemia.
- Trial name
- PIVOTAL (NCT07083206)
- Where
- South Korea
- Volunteers
- 4,500 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Prader-Willi Syndrome
A Study of Pitolisant in Participants With Prader-Willi Syndrome
The purpose of this study is to assess safety of pitolisant in eligible participants with Prader-Willi syndrome (PWS) who completed the End of Treatment (EOT) visit in a parent study (HBS-101-CL-002 [Open Label Extension (OLE)]…
- Trial name
- NCT07219485
- Testing
- Pitolisant
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Harmony Biosciences Management, Inc.
Diabetes Mellitus, Type 2
A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
This study is designed to examine the efficacy and safety of 2 dose levels of weekly subcutaneously injected albiglutide compared with placebo and an open label reference arm of daily subcutaneous injections of liraglutide, in…
- Trial name
- NCT01733758
- Testing
- Albiglutide 30 mg weekly, Albiglutide 50 mg weekly, Liraglutide 0.9 mg daily
- Where
- 74 sites in Japan
- Volunteers
- 494 people
- Sponsor
- GlaxoSmithKline
Cardiovascular Diseases
Evaluation of Atorvastatin Treatment on Carotid Plaque.
The purpose of the study is to evaluate the effect of 18 months treatment with atorvastatin 80mg or atorvastatin 10mg on the carotid vessel plaque morphology, in particular, the effect on evident necrotic lipid rich core of the…
- Trial name
- NCT00343655
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypercholesterolemia
A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants
This first-in-human (FIH) study of VXX-401, an anti-PCSK9 peptide-based immunotherapeutic candidate, is designed to assess the safety, tolerability, immunogenicity, and pharmacodynamics (PD) of VXX-401 and to determine an optimal…
- Trial name
- NCT05762276
- Testing
- VXX-401
- Where
- 5 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Vaxxinity, Inc.
Obesity & Overweight
A Study of SGB-7342 in Subjects With Obesity or Overweight
The purpose of this study is to evaluate the safety and tolerability of subcutaneously administered SGB-7342 in adult subjects with obesity and overweight.
- Trial name
- NCT07324850
- Testing
- SGB-7342
- Volunteers
- 45 people
- Sponsor
- Suzhou Sanegene Bio Inc.
Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
This study is designed to evaluate the dose range for MEDI0382 with respect to blood glucose control and weight loss effects, as well as to further explore the safety profile of MEDI0382
- Trial name
- NCT03235050
- Testing
- MEDI0382 low dose, MEDI0382 mid dose, MEDI0382 high dose
- Where
- 119 sites in United States, Bulgaria and 6 more
- Volunteers
- 834 people
- Sponsor
- AstraZeneca
Insulin Resistance
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (PEG)-BHD1028
Adiponectin has been known to play critical roles in various physio-regulatory processes, and adiponectin deficiency may contribute to insulin resistance. (PEG)-BHD1028 was developed as an agonist of adiponectin receptors.
- Trial name
- NCT06563115
- Testing
- (PEG)-BHD1028 Single Ascending Dose, (PEG)-BHD1028 Multiple Ascending Dose
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- EncuraGen, Inc
Obesity, Overweight
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight.
- Trial name
- NCT07684235
- Testing
- Maridebart cafraglutide
- Where
- 92 sites in United States, Australia and 3 more
- Volunteers
- 3,200 people
- Sponsor
- Amgen
Amyotrophic Lateral Sclerosis, ALS
A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS
69 subjects with ALS will be enrolled in the study and randomized at a 2:1 ratio to receive the study drug or placebo tablets. Randomization sequences will be in random block sizes and stratified for ENCALS risk category [high…
- Trial name
- PARADIGM (NCT05357950)
- Testing
- PrimeC
- Where
- 4 sites in Canada, Israel and 1 more
- Volunteers
- 69 people
- Sponsor
- NeuroSense Therapeutics Ltd.
Obesity
Evaluation of a Powered Stapler System on Surgical Interventions Required During Laparoscopic Sleeve Gastrectomy
This study will provide clinical data in an observational setting. Individuals undergoing LSG, and who meet study entry criteria, may be enrolled.
- Trial name
- NCT02358785
- Testing
- ECHELON FLEX™ Powered Plus Stapler
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Ethicon Endo-Surgery
Diabetes Mellitus, Type 2
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
This trial compare the use of two different doses of Empagliflozin to placebo, in T2DM patients on 16 wks linagliptin treatment and metformin background therapy.
- Trial name
- NCT01734785
- Testing
- Linagliptin, Empagliflozin + Linagliptin
- Where
- 90 sites in United States, Australia and 9 more
- Volunteers
- 607 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1
YpsoPump Occlusion Detection Algorithm: Collection of Real-world Data for In-silico Evaluation of a New Software Algorithm to Refine Occlusion Detection in Subjects With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
A common difficulty related to the insulin pumps are occlusions of the insulin infusion set (IIS). This study aims to evaluate the performance of a new software algorithm to detect catheter-occlusion in silico in order to refine…
- Trial name
- NCT05096325
- Testing
- YpsoPump® insulin pump system
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 40 people
- Sponsor
- mylife Diabetes Care AG
Hypercholesterolemia
Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects
Primary Objective: Injection Site Tolerability Secondary Objectives: To assess the safety profile of alirocumab SAR236553 (REGN727) To assess the pharmacokinetic-pharmacodynamic relationship of alirocumab SAR236553 (REGN727)
- Trial name
- NCT01443650
- Testing
- alirocumab SAR236553 (REGN727)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.